Brief: Alligator Bioscience Says Henlius Biotech Gets FDA IND Clearance For Phase 3 Initiation To Evaluate HLX22 (Ac101) In 1st Line HER2+ Advanced Gastric Cancer

Alligator Bioscience AB

21/05/2024 11:09

May 21 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * ANNOUNCES HENLIUS BIOTECH HAS RECEIVED FDA IND CLEARANCE
FOR
PHASE 3 INITIATION TO EVALUATE HLX22 (AC101) IN 1ST LINE HER2+
ADVANCED GASTRIC CANCER
    * FDA IND FOLLOWS PROMISING PHASE 2 RESULTS PRESENTED AT
2024 ASCO
GI REVEALING THAT ADDITION OF HLX22 (AC101) TO BIOSIMILAR
TRASTUZUMAB AND CHEMOTHERAPY LED TO DOSE-DEPENDENT INCREASE IN
PROGRESSION FREE SURVIVAL

Source text for Eikon:  ID:nMFNmN4Cm 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))